Lupin Launches Risperidone Long-Acting Injectable with Exclusivity
Global pharmaceutical leader Lupin Limited has announced an exciting development in the field of complex injectables. The company has recently unveiled its long-acting injectable of Risperidone, now available in 25 mg, 37.5 mg, and 50 mg single-dose vials in the U.S. This represents a significant milestone, as they attain 180-day CGT exclusivity following the approval from the U.S. Food and Drug Administration (FDA).
Advancements in Drug Delivery with PrecisionSphere™
At the heart of this innovative product is Lupin’s proprietary PrecisionSphere™ technology, developed by its subsidiary Nanomi B.V. This advanced long-acting injectable (LAI) platform has shown remarkable efficacy and safety in drug delivery systems. The microspheres created through this technology allow for extended-release profiles that can last weeks or even months, vastly improving patient experience with quicker and more efficient administration through smaller needles.
Moreover, Lupin’s approach towards partnership with other companies to extend product lifecycles using PrecisionSphere™ technology accentuates its commitment to more efficient patient care and access to treatments.
Significance of the Risperidone Launch
“The launch of Risperidone marks a significant milestone, demonstrating Lupin's expertise in delivering complex injectables to market, validating the capabilities of the PrecisionSphere LAI technology platform,” stated Spiro Gavaris, President of U.S. Generics at Lupin. This achievement not only signifies Lupin's innovative approach but also highlights their strategic goal of expanding their portfolio of complex products that benefit diverse patient populations.
Dr. Fabrice Egros, President of Corporate Development, further affirmed this commitment by stating, “PrecisionSphere's proven capabilities, combined with our track record of successful partnerships, uniquely position us to expand global access to advanced long-acting injectable treatments.” This quote underscores the collaborative philosophy Lupin embraces to make significant strides in patient care.
Risperidone’s Market Expectations
The newly launched Risperidone for extended-release injectable suspension is deemed bioequivalent and therapeutically equivalent to Risperdal Consta® Long-Acting Injection, utilized for the treatment of schizophrenia in adults. It is also suggested as a monotherapy or adjunctive therapy for maintenance treatment of bipolar I disorder.
With an estimated market valuation of USD 187 million for its combined strengths, the product is poised to make a substantial impact in the therapeutic areas it addresses, particularly in managing mental health conditions.
About Lupin Limited
Lupin Limited is recognized as a global leader in pharmaceuticals, with its headquarters based in Mumbai, India. They serve diverse markets across the globe, offering a wide array of branded and generic formulations, along with complex generics and biotechnology products. The company has become a trusted name in healthcare, excelling in various therapy areas such as respiratory, cardiovascular, and gastrointestinal.
With 15 advanced manufacturing facilities and 7 research centers around the world, Lupin employs more than 24,000 professionals dedicated to enhancing health outcomes. Their commitment to innovation is reflected through initiatives like Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, all aimed at ensuring comprehensive healthcare solutions are accessible to all.
Frequently Asked Questions
What is the significance of Lupin’s new Risperidone injectable?
The Risperidone injectable represents a significant innovation in long-acting injectables, enhancing treatment options for schizophrenia and bipolar disorder.
How does PrecisionSphere™ technology improve drug delivery?
This technology allows for the creation of uniform microspheres that enhance injectability and ensure consistent drug release over extended periods.
What are the potential uses of Risperidone by Lupin?
It is primarily indicated for treating schizophrenia and serves as a therapy option for maintenance treatment of bipolar I disorder in adults.
How does Lupin ensure global access to its products?
Lupin is expanding access through strategic collaborations and developing innovations that improve patient care and outcomes.
What other products does Lupin manufacture?
Lupin specializes in a range of pharmaceutical products, including complex generics, biotechnology products, and active pharmaceutical ingredients across various health areas.
